以接种反应程度观察疫苗的安全性；以血清抗体连续检测观察疫苗的血清学效果；以现场保护率观察疫苗的流行病学效果；以对比法观察疫苗免疫（感染）增强。结果表明疫苗接种反应率０８９％，其中中强反应率００３％；疫苗基础免疫完成后２周、加强前、加强后２周、加强后１年、加强后２年，血清中和抗体阳转率分别为７０００％、５０００％、９１１８％、５８９７％和３８８９％，荧光抗体阳转率分别为８３３３％、１２９０％、６４５２％、４１０３％和１３８９％；１９９５年１０月至１９９８年９月，试区接种人群疫苗保护率９４９９％；目前尚未发现接种人群有免疫（感染）增强问题。表明杭州天元生物药业公司生产的ＨＦＲＳ沙鼠肾细胞Ⅰ型灭活疫苗具有较好的安全性和近期（３年）防病效果。 The safety of the vaccine was observed by the degree of inoculation reaction. Serum antibody was continuously detected to observe the serological effect of the vaccine. The epidemiological effect of the vaccine was observed with the field protection rate. The immune (infection) enhancement was observed by the contrast method. The results showed that the vaccination response rate was 089%, of which the moderate response rate was 003%; two weeks after the completion of vaccine basic immunization, two weeks before strengthening, two years after strengthening, one year after strengthening, two years after strengthening, The positive rates of antibody positive were 7000%, 5000%, 9118%, 5897% and 3889%, respectively. The positive rates of fluorescence antibody were 8333%, 1290%, 64 52%, 4103% and 1389% respectively. From October 1995 to September 1998, the vaccination rate of the vaccinated people in the trial area was 9499%. No immunization (infection) enhancement was found in the vaccinated population. The results showed that HFRS gerbil nephropathy type I inactivated vaccine produced by Hangzhou Tianyuan Bio-pharmaceutical Company had good safety and the recent (3 years) preventive effect.